BU-NOT-SET

CONTACT US
Serialisation efforts must push ahead despite deadline extension
  • Manufacturing
Eyes
Insight
Metal coordinated pharmaceuticals: a new and promising technology
  • Drug product
Eyes
Insight
Optimising excipient selection
  • Drug product
Eyes
Insight
Serialisation stragglers: Industry concern for complacency
  • Manufacturing
Eyes
Insight
The race against the serialisation deadline
  • Manufacturing
Eyes
Insight
Why tomorrow is too late to start your serialisation preparations
  • Manufacturing
Eyes
Insight
The serialisation landscape: Challenges and opportunities for a CDMO
  • Manufacturing
Eyes
Insight
Aseptic manufacturing trends roundtable
  • Industry trends
Eyes
Insight
Developing a high throughput screening method
  • Drug substance
Eyes
Insight
Insight
  • Industry trends
A CDMO’s insight into the pharma M&A landscape
Insight
  • Industry trends
Recipharm’s continuous global support throughout the COVID-19 pandemic
Insight
  • Manufacturing
Is outsourcing the most viable pathway for innovators?
Case study
  • Drug product
Developing a generic prolonged-release isosorbide-5-mononitrate tablet
Insight
  • Industry trends
Recipharm Wins two 2020 CMO Leadership Awards
Insight
  • Corporate
Recipharm’s global teams support and engage with their local communities in the fight against COVID-19
Insight
  • Manufacturing
Recipharm launches new virtual inspection and audit tool for customers, in light of COVID-19 outbreak
Brochure
  • Corporate
Recipharm 25 years
Fact sheet
  • Drug substance
API product list